Cephalon, Inc. was an American biopharmaceutical company co-founded in 1987 by pharmacologist Frank Baldino, Jr., [1] neuroscientist Michael Lewis, and organic chemist James C. Kauer—all three former scientists with the DuPont Company.

On October 14, 2011, Cephalon Inc. became a wholly owned subsidiary of Teva and ceased to be traded on NASDAQ.

Cephalon, Inc. is an international biopharmaceutical company that specializes in drugs to treat neurological and sleep disorders. The company's activities encompass the discovery, research, and development of new treatments as well as the sales and marketing of finished products.

Cephalon Inc. was established in 1987 as a global biopharmaceutical company dedicated to discovering, developing and bringing to market medications to improve the quality of life of individuals...

Oct 18, 2011 · Teva Pharmaceutical Industries, a global generic drug maker, has acquired Cephalon. Following the merger agreement between the parties, each share of Cephalon common stock has been converted into the right to receive $81.50 in cash.

May 2, 2011 · NEW YORK (Reuters) - Teva Pharmaceutical Industries Ltd struck a deal to acquire U.S. specialty drugmaker Cephalon Inc for nearly $7 billion, topping an unsolicited bid by Canada's Valeant ...

May 2, 2011 · Teva Pharmaceutical Industries Ltd. has agreed to buy Cephalon Inc. for $6.8 billion in a deal that would give the world's largest generic drug developer a range of biotechnology drugs...